Piflufolastat F 18 is a radiographic agent used in positron emission tomography (PET) for the detection of prostate cancer. Approved by the USFDA in 2021 for use as a diagnostic agent for prostate cancer, it binds strongly to prostate-specific membrane antigen (PSMA), a protein that is overexpressed in prostate cancer and other solid tumours. Tracers labelled with 18F have longer decay half-lives, shorter positronic ranges and higher positronic yields, thus providing higher resolution PET images for medical diagnostics.
